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ABSTRACT
Although human herpesvirus 6 (HHV-6) has been considered an important opportunistic and potentially fatal
pathogen for allogeneic hematopoietic stem cell transplantation (HSCT), the clinical significance of HHV-6
reactivation remains controversial. In this study, we monitored HHV-6 DNAemia in 72 consecutive allogeneic
HSCT recipients by real-time quantitative polymerase chain reaction. A total of 680 peripheral blood speci-
mens were collected from the recipients before HSCT or at weekly intervals after HSCT. As the predominant
variant, HHV-6B was detectable at least once in 47.2% (34/72) of HSCT recipients on the median day 21
(range, 7–84 days); HHV-6A reactivation occurred in only 1 recipient (1.4%). Detectable HHV-6B reactivation
was associated with increased probability of skin rash by day 30 after HSCT (hazard ratio [HR], 3.68; 95%
confidence interval [CI], 1.24–10.92; P  .019), cytomegalovirus (CMV) antigenemia (HR, 2.35; 95%CI,
1.32–4.19; P  .004), and hemorrhagic cystitis (HC) (HR, 2.59; 95%CI, 0.96–6.98; P  .061) by day 100 after
HSCT. Neutrophil and platelet engraftment, mortality for 100 days after HSCT were not affected by HHV-6B
reactivation. In conclusion, HHV-6 reactivation is a common event, and this study demonstrates a correlation
between HHV-6B infection and CMV reactivation, early rash, and possibly increased incidence of HC after
transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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PNTRODUCTION
Like all of the other herpesviruses, human herpes-
irus 6 (HHV-6) has a tendency to establish latent
nfection in host cells after primary infection and may
eactivate in immunocompromised situations, espe-
ially in the setting of allogeneic hematopoietic stem
ell transplantation (HSCT). Two genetically distinct
ariants of HHV-6 have been identiﬁed, A and B.
HV-6B often reactivates in HSCT patients [1] and
as been recognized as an important opportunistic
athogen for post-HSCT recipients. It has been re-
orted that HHV-6 reactivation is associated with
elayed platelet engraftment or myelosuppression
2,3], skin rash with or without acute graft-versus-host
isease (aGVHD) [4], interstitial pneumonitis [5], and aytomegalovirus (CMV) disease [6]. Due to its neuro-
ropism, HHV-6 is also an important pathogen of
ncephalitis after HSCT and has been studied exten-
ively [7,8]. Nonetheless, the full clinical signiﬁcance
f HHV-6 reactivation after HSCT remains to be
lariﬁed.
The purpose of the present study is to investigate
he importance of active HHV-6 infection in the de-
elopment of early clinical complications and end-
oints after HSCT.
ATERIALS AND METHODS
atients
Our study subjects were patients who underwent
llogeneic HSCT between May 2004 and June 2005 at
1031
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L.-R. Wang et al.1032eking University Institute of Hematology and Dao
ei Hospital, Beijing. The subjects were treated by the
ame team of attending physicians. Blood samples
ere collected prospectively from each subject before
ransplantation and then weekly until 12 weeks after
SCT or discharge. The clinical data were analyzed
etrospectively. Two subjects who experienced early
eath before day 21 (1 from multiorgan failure and the
ther from respiratory failure after transplantation).
ltogether, 72 patients were enrolled in our study. A
otal of 680 EDTA-anticoagulated peripheral blood
amples were obtained. Informed consent for this
tudy was obtained from the Institutional Review
oard at Peking University Institute of Hematology,
nd each subjects or a guardian signed a consent form.
The 72 subjects included 41 males and 31 females,
ith a median age of 28 years (range, 8–58 years).
iagnoses included acute leukemia (n  37), chronic
yeloid leukemia (n 22), myelodysplastic syndrome
n  3), aplastic anemia (n  3), non-Hodgkin’s lym-
homa (n  6), and multiple myeloma (n  1). Forty-
even of the patients with matched sibling donors
ere conditioned with Bu/Cy2 or Cy/total body ir-
acdiation (TBI), whereas 25 of the patients with
atched unrelated or mismatched related donors were
onditioned with Bu/Cy2 plus antithymocyte globulin
ATG) [9]. Prophylaxis for aGVHD consisted of cy-
losporin A, mycophenolate mofetil, and a short
ourse of methotrexate. The ﬁrst-line therapeutic reg-
men for aGVHD was intravenous methylprednisone.
ll patients received intravenous ganciclovir from day
9 to day 2 (5 mg/kg, twice daily) and acyclovir
rally from day 1 to day 30 (400 mg, twice daily).
MV antigenemia was monitored weekly after the
ngraftment of neutrophils. Adenovirus and HHV-7
NAemia were routinely monitored by polymerase
hain reaction (PCR). Epstein-Barr virus and human
implex virus 1 and 2 were monitored by enzyme-
inked immunosorbent assay. Preemptive therapy
gainst CMV infection with ganciclovir or foscarnet
as administered after CMV antigenemia was con-
rmed [9].
eal-Time Quantitative PCR Amplification
DNA was extracted from peripheral blood mono-
uclear cells (PBMCs) using a whole-blood genome
NA extraction kit (Tiangen, China) according to the
anufacturer’s instructions. A real-time quantitative
CR (RQ-PCR) assay for the detection of HHV-6
NAemia in PBMCs was performed with an ABI
500 Real-Time PCR System (Applied Biosystems,
oster City, CA), and the data were analyzed by Se-
uence Detection System software, version 1.2 (Ap-
lied Biosystems). The RQ-PCR primers and probe
or HHV-6 were described previously [10]. Human
ecombination activating gene 1 (RAG1) was used as dn internal reference; the primers and probe of RAG1
ere described previously [11]. The RQ-PCR reac-
ion was performed in a ﬁnal volume of 25 L con-
aining Taqman Universal PCR Master Mix (Applied
iosystems), 830 nM each of primer, 100 nM of Taq-
an probe, and 100 ng of DNA template. The Taq-
an PCR cycling conditions were as follows. After
min at 50°C and 10 min at 95°C, samples were
ubmitted to 40 cycles, each comprising 15 s at 95°C
nd 60 s at 62°C. A standard PCR assay curve of
HV-6 was generated using serially diluted plasmid
102–107 copies per well), containing HHV-6 target
ragment (kindly donated by Dr. Zerr, University of
ashington). The HHV-6 DNA copies were deter-
ined by comparing the data with the standard curve
nd were expressed as the number of HHV-6 equiv-
lent genome copies per 106 PBMCs (copies/106 PB-
Cs). The sensitivity of Taqman assays for HHV-6
as 10 copies, determined using the serial dilution of
lasmid standards. All standards and samples were
ssayed in duplicate.
ested PCR and Subtype Determination
f HHV-6
Nested PCR was used to amplify a fragment of
31 gene consensus sequence for HHV-6 variants A
nd B. This fragment included a Hind III restriction
ite for HHV-6B, which is absent in type A. The
equences of outer primers amplifying a 1216-bp frag-
ent and inner primers amplifying a 492-bp fragment
ere described previously [12]. A 100-ng DNA sam-
le was used as a template for ﬁrst-step PCR ampliﬁ-
ation in a 50-L PCR mixture containing PCR
uffer (including 10 mM of Tris-HCl [pH 8.3], 50
M of KCl, and 1.5 mM of MgCl2), 200 nM of each
eoxynucleotide triphosphate, 400 nM of each outer
rimer, and 1.25 U of Taq-polymerase (TaKaRa,
alian, China). The thermal cycling conditions were
nitial denaturation of the DNA template at 94°C for
min, followed by 35 cycles at 94°C for 30 s, 55°C for
0 s, and 72°C for 60 s, and then ﬁnal extension at
2°C for 7 min. A 2-L sample of the ﬁrst-round
CR product was used as a template for the second-
tep PCR, which was carried out under the same
onditions except using inner primers. The ampliﬁed
roducts that were positive for HHV-6 were incu-
ated for 1 h at 37°C with Hind III enzyme (TaKaRa).
he PCR amplicon of HHV-6 was cleaved by Hind
II to 370-bp and 122-bp fragments for variant B,
hereas variant A remained uncut.
efinitions
The criterion for neutrophil engraftment was an
bsolute neutrophil count  0.5  109/L for 3 con-
ecutive days during the study period, counting the
ay of engraftment as the ﬁrst day. The criterion for
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HHV-6B and Complications after HSCT 1033latelet engraftment was a platelet count  20 
09/L for 7 consecutive days independent of transfu-
ion during the study period, counting the day of
ngraftment as the ﬁrst day. Acute GVHD was de-
ned and graded by previously published criteria
13,14]. CMV infection was deﬁned as 1 cell per 105
BMCs positive for CMV pp65 antigen, and CMV-
elated interstitial pneumonia (IPn) was deﬁned ac-
ording to previously reported criteria [15]. HHV-6
eactivation was deﬁned as the detection of HHV-6
iral DNA per 10 copies/106 PBMCs. Skin rash re-
erred to maculopapular rash except for drug eruption.
ccording to the onset time, skin rash occurring by
ay 30 after HSCT was considered early rash. Mor-
ality was deﬁned as death due to any cause after
ransplantation. To explore the impact of HHV-6
iral load on the clinical complications, 72 patients
ere divided into high viral load ( 5000 copies/106
BMCs), intermediate viral load (100–5000 copies/
06 PBMCs) and low viral load or without HHV-6B
eactivation ( 100 copies/106 PBMCs) groups.
tatistical Analyses
Univariate probabilities of time to HHV-6B and
MV reactivation and HHV-6B by load were calcu-
ated using cumulative incidence curves to accommo-
ate competing risks. The associations between HHV-
B reactivation and clinical events of engraftment,
kin rash, CMV, HC, and mortality by days 30, 50,
nd 100 after HSCT were examined. None of our 72
atients died within 30 days after HSCT. The per-
entages of clinical events by HHV-6B reactivation
tatus (yes vs no) by day 30 were reported. The 2 test
as used to evaluate the equal percentages of clinical
vents in these 2 cohorts with or without HHV-6B
eactivation (Table 1). What happened for patients
ho died within day 50 or within day 100 without
eveloping HHV-6B or certain clinical events was
nknown. The Cox proportional hazards regression
odel was used to analyze each clinical event, in
hich HHV-6B was treated as a time-dependent co-
ariate; that is, the patient was considered to have
able 1. The Association Between HHV-6B Reactivation and Clinical
vents by 30 Days After HSCT
Clinical Events
by Day 30
No. of
Events
HHV-6B
Reactivation Status
PNo Yes
NC > 0.5  109/L 71 44 (97%) 27 (100%) .435
latelet > 20  109/L 54 31 (69%) 23 (85%) .122
kin rash 27 9 (20%) 18 (66%) <.0001
MV 7 4 (9%) 3 (11%) .758
C 7 3 (7%) 4 (15%) .259
patient was considered as to have HHV-6B reactivation (yes) if he
or she had HHV-6B reactivation by day 30 of HSCT.HV-6B reactivation only if the current study time Hassed his or her onset time of HHV-6B reactivation.
he 2 test was used to evaluate the association be-
ween HHV-6B viral load and clinical events. All
eported P values were 2-sided, and a P value  .05
as considered statistically signiﬁcant.
ESULTS
HV-6 Reactivation
HHV-6 DNA was quantiﬁable at least once in 35
f the 72 patients (48.6%) after HSCT using RQ-
CR on median onset day 21 (range, 7–84 days). The
uration of positive PCR was 2 weeks in 19 patients
26.4%), 3 weeks in 15 patients (20.8%), and 4 weeks
n 10 patients (13.9%). As the predominant variant,
HV-6B DNA was detected at least once in 34 pa-
ients (47.2%); HHV-6A reactivation occurred in only
patient (1.4%) after HSCT. The detailed viral load
nd sequence characteristics of the patients with
HV-6A reactivation have been described previously
16]. Cumulative incidence of HHV-6B reactivation
fter HSCT is shown in Figure 1A. HHV-6B reacti-
ation occurring within the ﬁrst 30 days after HSCT
as seen in 37.5% (27/72) of the patients in this
ohort. Most of HHV-6B infection occurred between
eeks 2 and 7 after HSCT (Figure 1B). Quantitative
nalysis of viral load indicated that the median
igure 1. Cumulative incidence (A) and kinetics (B) of HHV-6B
nd CMV reactivation in post-HSCT patients. Week, weeks after
SCT; n, number of available samples at each study occasion.
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L.-R. Wang et al.1034HV-6B viral level was 368 copies/106 PBMCs
range, 12–285,167 copies/106 PBMCs) in the patients
ith HHV-6B reactivation, and that the peak of
HV-6B viral load was reached during week 3, at
hich point the median level of DNA loads could be
s high as 2562 copies/106 PBMCs (range,  10–
7,950 copies/106 PBMCs). Figure 2 shows the cu-
ulative incidences of high, intermediate, and low
iral loads of HHV-6B in this cohort. The patient
ith HHV-6A reactivation presented with no signif-
cant complications during the 4-week follow-up after
ransplantation. The association between HHV-6B
eactivation and clinical events was subsequently ana-
yzed.
HV-6B and Engraftment
Table 1 indicates the association between HHV-6B
eactivation and clinical endpoints by day 30 after
SCT. All but 1 of the patients had achieved full
eutrophil engraftment by this time; the remaining
atient achieved neutrophil engraftment 31 days after
SCT. Platelet engraftment was obtained in 54 of the
atients (75%) by day 30 after HSCT. Neither neu-
rophil nor platelet engraftment was signiﬁcantly in-
uenced by HHV-6B reactivation by days 30, 50, and
00 after HSCT (Tables 1 and 2).
HV-6B and Skin Rash
Half of the patients (36/72) experienced skin rash
ithin 100 days after HSCT. Skin rash occurring by
ay 30 after HSCT (considered early rash) was found
n 37.5% (27/72). Early rash was more frequently
iagnosed in patients with HHV-6B reactivation after
SCT than in those without HHV-6B reactivation
fter HSCT (20% vs 66%, P  .0001 [Table 1];
azard ratio [HR], 3.68; 95% conﬁdence interval [CI],
.24–10.92; P  .019 [Table 2]). Patients with high
nd intermediate viral loads of HHV-6B had a greater
robability of experiencing early rash compared with
igure 2. Cumulative incidence of HHV-6 reactivation according
o HHV-6B viral loads.hose with low viral load or without HHV-6B reacti-ation (63.6% [7/11], 64.7% [11/17], and 20.5%
9/44], respectively; P  .001). The prevalence of skin
ash by days 50 and 100 after HSCT in the patients
ith and patients without HHV-6B reactivation was
ot signiﬁcantly different (P .364 by day 50 and P
273 by day 100; Table 2). Corticosteroids were ad-
inistered to 26 of the 27 patients with early rash. In
hese patients, HHV-6 reactivation was maintained
or  2 weeks in 15 and for at least 3 weeks in 11. In
he single patient who did not receive corticosteroids,
HV-6 reactivation occurred only once after HSCT.
HV-6B and CMV
The cumulative incidence of CMV antigenemia is
hown in Figure 1A. CMV antigenemia was detected
t least once in 65.2% (47/72) of post-HSCT patients
n median day 43 (range, 14–100 days). Most cases of
MV antigenemia occurred between the weeks 4 and
after HSCT (Figure 1B).
HHV-6B reactivation occurred earlier than CMV
ntigenemia in all but 3 patients. Compared with the
atients without HHV-6B reactivation, those with
able 2. HHV-6B Reactivation as a Time-Dependent Risk Factor for
he Analysis of Clinical Events in Patients by 30, 50, and 100 Days
fter HSCT
Events No. of Events HR (95% CI) P*
NC > 0.5  109/L†
By day 30 71 2.28 (0.86–6.06) .097
By day 50 71 2.28 (0.86–6.06) .097
By day 100 71 2.28 (0.86–6.06) .097
latelet > 20  109/L
By day 30 54 1.12 (0.49–2.56) .782
By day 50 61 1.02 (0.47–2.19) .966
By day 100 65 0.87 (0.41–1.83) .707
kin rash
By day 30 27 3.68 (1.24–10.92) .019
By day 50 33 1.61 (0.57–4.56) .364
By day 100 37 1.67 (0.67–4.14) .273
MV
By day 30 7 2.09 (0.46–9.41) .337
By day 50 33 2.20 (1.10–4.38) .026
By day 100 47 2.35 (1.32–4.19) .004
C
By day 30 7 2.46 (0.49–12.31) .274
By day 50 15 2.06 (0.72–5.91) .180
By day 100 17 2.59 (0.96–6.98) .061
ortality
By day 30 — — —
By day 50 4 1.31 (0.18–9.35) .787
By day 100 11 0.69 (0.20–2.35) .548
We further compute the adjusted RR when unadjusted RR had P
.10. We considered a forward stepwise modeling approach to
identify other signiﬁcant covariates. Mainly a conditioning reg-
imen with HLA-matching type/ATG was signiﬁcant.
Of the 34 patients with HHV-6B reactivation, 30 had ANC 
0.5  109/L before HHV-6B reactivation and only 4 had
HHV-6B before ANC  0.5  109/L. It may make sense to
evaluate the effect of HHV-6B reactivation on achieving
ANC  0.5  109/L and the same as in the analysis of platelet
engraftment.
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HHV-6B and Complications after HSCT 1035HV-6B reactivation had a higher probability of sub-
equently experiencing CMV antigenemia by day 50
HR, 2.20; 95%CI, 1.10–4.38; P .026; Table 2) and
ay 100 (HR, 2.35; 95%CI, 1.32–4.19; P  .004;
able 2) after HSCT.
A positive association was also noted between
HV-6B viral load and CMV antigenemia. Patients
ith high and intermediate HHV-6B viral loads had a
igher probability of developing CMV antigenemia
han those with low viral load or without HHV-6B
eactivation (100% [11/11], 82% [15/17], and 47.7%
21/44], respectively; P  .0001).
HV-6B and Central Nervous System Events
Central nervous system (CNS) events were ob-
erved in only 3 of the 72 patients (4.2%). However, a
iagnosis of HHV-6-related CNS dysfunction could
ot be established, because HHV-6 DNA testing of
erebrospinal ﬂuid samples from these patients was
ot performed. Two of the patients developed confu-
ion, agitation, and seizures simultaneous with HHV-
B reactivation. Moreover, along with consecutive
HV-6B replication, high viral loads were also seen
n these 2 patients, who had median viral copies of
3,240 copies/106 PBMCs (range, 2196–53,860 cop-
es/106 PBMCs) and 1485 copies/106 PBMCs (range,
51–27,950 copies/106 PBMCs). One patient experi-
nced seizures 50 days after HHV-6B reactivation
ith a viral load of 250 copies/106 PBMCs.
HV-6B, HC, and -IPn
HC occurred in 17 of the 72 patients (23.6%); 14
f these 17 patients (82.4%) experienced HHV-6B
eactivation. HHV-6B reactivation was positively as-
ociated with higher incidence of HC by day 100 after
SCT, but the association was of borderline statis-
ical signiﬁcance (HR, 2.59 [0.96–6.98]; P  .061;
able 2). Moreover, patients with high and interme-
iate HHV-6B viral loads had a higher probability of
C than those with low viral load or without HHV-6B
eactivation (54.5% [6/11], 35.3% [6/17], and 11.4%
5/44], respectively; P  .006). In addition to HHV-
B, CMV reactivation was also observed in 15 of the
7 patients with HC. No adenovirus DNA was de-
ectable in these patients with HC.
IPn occurred in 7 of the 72 patients (9.7%); 4 of
hese 7 patients had HHV-6B infection. Statistical
nalysis could not be performed here due to the lim-
ted number of cases.
HV-6B and Mortality
No signiﬁcant correlation was found between
HV-6 reactivation and mortality by day 50 and day
00 after HSCT (Table 2). uISCUSSION
This study on HHV-6 reactivation in allogeneic
SCT recipients has demonstrated that HHV-6B is
common pathogen in post-HSCT recipients, con-
istent with previous ﬁndings [17,18]. Moreover,
HV-6B reactivation may be associated with some
arly clinical events after HSCT. Our data also indi-
ate the correlation between HHV-6B/CMV reacti-
ation and the development of acute GVHD. A re-
ated description will be reported in a future paper.
Clinical evidences of the correlation between
HV-6 and CMV infection has been accumulated
ainly from studies on solid organ transplantation
6,19] and allogeneic bone marrow transplantation
20]. A positive association between HHV-6 reactiva-
ion and subsequent CMV antigenemia was also found
n the present study. It is well known that reactiva-
ion of HHV results from an immunocompromised
ituation caused by the conditioning regimen before
ransplantation and the use of immunosuppressive
gents for aGVHD prophylaxis during transplanta-
ion. Lately, HHV-6 has been considered an immu-
osuppressive virus. Although the precise mechanism
y which HHV-6 impairs immunologic function is
ot completely clear, available evidence favors the
ypothesis that HHV-6 may exacerbate the immno-
ompromised state through the direct destruction of
cells [21], altering the expression of molecules im-
ortant in the antigen-presenting process [22] or af-
ecting the production of cytokines, including inter-
eukin (IL)-1	 and tumor necrosis factor (TNF)-

23]. HHV-6 shares some molecular and biological
roperties with CMV, including DNA sequence ho-
ology, genomic organization, antigenic cross-reac-
ivity, and in vitro growth characteristics [24]. CMV
nd HHV-6 reactivation should be considered indica-
ors of a severe immunocompromised situation in re-
ipients in need of more aggressive antiviral therapy.
hether HHV-6B can aggravate the immunocom-
romised status to facilitate or directly cause CMV
nfection cannot be determined from our results. Ad-
itional studies are needed to investigate the exact
elationship between HHV-6 and CMV and to pro-
ide rational guidance for therapeutic strategies.
Skin rash is one of the most frequently observed
ymptoms in post-HSCT recipients, especially during
he ﬁrst 30 days after HSCT. The present study dem-
nstrates that patients with HHV-6B reactivation
ave increased probability of developing early rash.
hat HHV-6 can reach skin tissue during the period
f viremia was demonstrated in a previous study; it
as suggested that the active HHV-6 infection may
lay an important role in the development of rash [4].
kin rash after HSCT is a major symptom of aGVHD.
he appearance of rash within 30 days after HSCT is
sually considered aGVHD-related; however, rash
a
t
a
p
l
m
t
H
p
f
3
c
t
H
a
m
i
B
i
p
H
t
r
p
c
a
A
H
p
H
H
t
a
t
A
H
T
c
e
a
s
t
r
H
A
a
t
a
s
o
f
R
i
H
H
p
r
R
1
1
1
1
1
1
L.-R. Wang et al.1036lso is the main symptom of active HHV-6B infec-
ion [25].
HHV-6 can establish latent infection in the CNS
fter primary infection and later reactivate in the hip-
ocampus, causing limbic encephalitis and temporal
obe epilepsy in both immunocompromised and im-
unocompetent hosts [26]. A close association be-
ween HHV-6 infection and CNS complications after
SCT has been reported previously [7,8]. In the
resent study, although only 3 patients had CNS dys-
unction, active HHV-6B infection was veriﬁed in all
of these patients. However, the unavailability of
erebrospinal ﬂuid specimens made it difﬁcult to fur-
her demonstrate any sound pathogenic link between
HV-6B and CNS complications.
HC is an important complication after HSCT,
nd many factors may be responsible for its develop-
ent. In the present study, HC commonly occurred
n patients with both HHV-6B and CMV reactivation.
ut the data fail to indicate adenovirus as a pathogen
n HC, due to the negative results. Nonetheless, the
robability of other viruses as coexisting pathogens of
C cannot be eliminated in the present study, because
he available panel for various types of virus detection
emains limited. IPn has already been reported in
revious studies [27,28]; but the limited number of
ases in our cohort makes it difﬁcult to evaluate the
ssociation between HHV-6B reactivation and IPn.
lthough some previous studies have reported that
HV-6 reactivation might be involved in delayed
latelet engraftment [2,16,29] and mortality after
SCT [16], the present study found no evidence that
HV-6 reactivation affects these clinical endpoints.
Multivariate analyses were conducted to explore
he association between HHV-6B reactivation and the
forementioned clinical events. The results indicated
hat a conditioning regimen with HLA-matching type/
TG was the only covariate of statistical signiﬁcance.
HV-6B infection after HSCT was not signiﬁcant.
his ﬁnding may be due to the limited number of
ases.
In summary, HHV-6B reactivation is a common
vent closely associated with early skin rash, CMV
ntigenemia, and possibly HC after HSCT. Further
tudies are needed to investigate the effect of preemp-
ive therapy on controlling HHV-6 viral loads and
educing the risk of complications likely caused by
HV-6.
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